Eric Messner, Emalex Biosciences CBO
A Chicago biotech skips the IPO in favor of late-stage Series D for a PhIII Tourette drug
Emalex Biosciences has secured $250 million in Series D funds to bankroll a Phase III clinical trial in children, adolescents and adults who have Tourette …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
